For many years, the key regulatory role of ACC1 in fatty acid metabolism makes it attractive therapeutic targets for various metabolic diseases including non-alcoholic fatty liver disease, obesity and diabetes. This evidence concerns the gene ACACA and metabolic dysfunction-associated steatotic liver disease.